STRIDE-RCT: testing multi-cancer blood tests in NHS diagnostic pathways

What the trial will assess

This Is the Coast and Men’s Health report that STRIDE-RCT is set to assess blood tests in more than 20,000 patients across around 200 GP surgeries in England. The reported focus is people aged 45 and over who have abdominal symptoms. The central question is whether these tests may support earlier cancer detection while reducing unnecessary hospital investigations.

The population described in the reports is important to the scope of the study: these are people with symptoms, rather than an explicitly described programme for testing people without symptoms. The findings will therefore need to be understood in relation to the patients and diagnostic setting being studied. Whether results could apply to other populations is not yet clear.

How the tests work

According to the coverage by This Is the Coast and Men’s Health, the approaches being assessed include protein measurements and artificial intelligence analysis to identify signals associated with several cancers. The reported aim is to explore whether information from a blood sample may help with cancer detection within general practice.

However, the effectiveness of these approaches in that setting remains unproven, according to the reports. Identifying a signal associated with cancer and showing that a test improves a diagnostic pathway are distinct questions. In the context of the reported trial aims, the practical issue is not simply whether a blood test produces a result, but whether its use may support earlier detection without generating unnecessary investigation.

Questions for diagnostic pathways

This Is the Coast and Men’s Health describe earlier detection and fewer unnecessary hospital investigations as questions for the trial, not established benefits. It is not yet clear how large any effect might be, which patients might benefit, or whether the study will show an improvement on both measures.

The reports’ stated focus also leaves an important operational question: how would a blood-test result fit alongside existing assessment and referral decisions? The precise way results will influence subsequent investigations is not yet clear from the information provided. It would therefore be premature to describe these tests as replacements for particular diagnostic procedures.

Why surgeons may be interested

For surgeons, the trial objectives reported by This Is the Coast and Men’s Health raise questions about possible changes to cancer referral pathways and demand for investigations such as colonoscopy. These are potential implications of the research, rather than reported findings. Whether investigation numbers would fall, rise or shift between groups of patients is not yet clear.

The distinction between an earlier cancer diagnosis and a reduction in investigations will be particularly relevant when interpreting the study. Both are reported aims, but neither can yet be assumed. Any discussion of future surgical workload would need evidence about what happens after testing, not just the number of blood tests performed.

What remains to be established

Taken together, the accounts from This Is the Coast and Men’s Health describe an evaluation of a possible diagnostic approach, rather than proof of routine clinical effectiveness. The available information does not yet make clear the timetable for results or the eventual implications for wider NHS use. For now, the reported scale and primary-care focus explain the trial’s relevance, while its practical effects remain open questions.

This article is an overview for information only; readers should consult the original sources and appropriate professional guidance.